- Home
- NUVL vs DSGX Comparison
NUVL vs DSGX Comparison
Compare NUVL & DSGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NUVL | DSGX |
|---|---|---|
| Founded | 2017 | 1981 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 7.6B |
| IPO Year | 2021 | 1999 |
Fundamental Metrics
Financial Performance| Metric | NUVL | DSGX |
|---|---|---|
| Price | $100.82 | $65.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $135.00 | $114.78 |
| AVG Volume (30 Days) | 497.6K | ★ 820.1K |
| Earning Date | 02-27-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.65 |
| EPS | N/A | ★ 1.78 |
| Revenue | N/A | ★ $703,706,000.00 |
| Revenue This Year | N/A | $12.40 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $36.36 |
| Revenue Growth | N/A | ★ 11.39 |
| 52 Week Low | $55.54 | $62.56 |
| 52 Week High | $113.02 | $117.35 |
Technical Indicators
Market Signals| Indicator | NUVL | DSGX |
|---|---|---|
| Relative Strength Index (RSI) | 49.64 | 25.29 |
| Support Level | $98.65 | $62.56 |
| Resistance Level | $106.57 | $69.91 |
| Average True Range (ATR) | 4.46 | 3.25 |
| MACD | -0.29 | -0.65 |
| Stochastic Oscillator | 47.36 | 12.06 |
Price Performance
Historical ComparisonAbout NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About DSGX Descartes Systems Group Inc. (The)
Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.